Making a better patent

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Making a better patent

Patent prosecution is taking place against a backdrop of the press claiming many patents should not have been issued, allegations that patent examiners shirk their responsibilities and the technology industry being exasperated by the Alice aftermath

It's been a tough few years for the patent system. The press has latched onto claims that patents have been issued that shouldn't have been, allegations have been leveled that patent examiners shirk their responsibilities, and the technology industry has been exasperated by the aftermath of the Alice decision. "Making a Better Patent," clearly means doing so at multiple levels, and a panel of the same name at the AIPLA Annual Meeting today will address each.

The first stop on the way to a better patent is the USPTO itself. It has not been deaf to criticism and, in response, has introduced a number of initiatives to improve its performance. "My speculation is that the public press has been slamming patents recently, saying patents have poor quality, and I think this is the administrative response to those pronouncements in the press," says Paul Kitch of Nixon Peabody.

Kitch will moderate a session today that will include a presentation by Valencia Martin-Wallace, Deputy Commissioner for Patent Quality of the USPTO, updating practitioners on what they need to know about these quality improvement initiatives. These efforts include the Post-Prosecution Pilot (P3) program, which uses a number of metrics to analyze the expediency of patent examinations from application submission to first office action. The P3 program is intended to "allow for more streamlined prosecution, and hopefully shorter timelines," says Kitch. "If patent examiners do a high quality job at the beginning, it will make everything easier for prosecutors down the road," he says.

Accusations of overly-broad patent claims have haunted patent practitioners, and, in some cases, resulted in expensive district court and Federal Circuit litigation where they've been reprimanded for this practice. But, as Kitch puts it, "attorneys have a duty to their clients to seek the broadest possible claims," in order to provide the broadest protection possible.

Bryan Wheelock, a partner at Harness Dickey & Pierce, will discuss the reasons that, in spite of some public perception, drafting broad claims is still essential for patent applicants, so long as it's done responsibly. Kitch says drafting narrow claims may protect an inventor from having his patent rejected, but ultimately, narrow claims "make it easier for people to take the inventor's ideas and invention, make slight changes and deprive the inventor and the company of the benefit of their own invention."

But making better patents isn't just about best administrative and drafting practices. Ultimately, "you only get a better patent if you get a patent, period," says Kitch. The panel's final speaker, James Hallenbeck, of Schwegman Lundberg & Woessner, will examine threats to the patent system as a whole, and how they might be addressed. "This is a sharply divided issue," says Kitch. Many arguments have been made that technologies for biopharmaceutical and software should not be patentable, "and, therefore, the better patent is one that doesn't exist at all," he says.

But doing away with patents for these technologies could do irreparable harm, not only to important areas of innovation but to the US economy as a whole, Wheelock will argue. Ten years ago, Microsoft was among the six largest companies in the country, but was joined in the top ranks by energy and financial companies. Now, five of those top six companies are software-based or related. So, "hurting the US patent system to deprive software, and the largest industries in the US, where we have a competitive edge, only hurts US companies," says Kitch.

more from across site and SHARED ros bottom lb

More from across our site

As revenue reporting season hits full stride, firms have made a point of highlighting the successes of their IP teams as they take centre stage in big-ticket work
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US
The firm, which represented Getty in one of the most closely followed copyright cases in recent years, said IP was among its standout practice areas
The decision to divide was partly due to differing visions over the impact of technology on IP work, according to one partner
The Bar Council of India’s warning to Dentons Link Legal and CMS IndusLaw shows why foreign firms are right to worry about India’s legal market
News of a trade secrets leak involving TSMC and an action in Japan against AI startup Perplexity were also among the top talking points
Rothwell Figg partner Leo Loughlin discusses the importance of pro bono work and why ‘For the Kids’ should not be monopolised for trademark purposes
A new consultancy firm, set up by a former Warner Bros and Netflix lawyer, aims to resolve tensions between AI developers and the creative industries
Raúl Rubio, partner at Pérez-Llorca, outlines the firm’s AI initiatives and says solutions for law firms have yet to reach the required level of sophistication
MBIP principals Andy Mukherji and Ellen Reid discuss the firm’s combination with Jones Tulloch and reveal why younger firms stand to gain from AI demand
Gift this article